Impact of multiangular information on empirical models to estimate canopy nitrogen concentration in mixed forest

Directional effects in remotely sensed reflectance data can influence the retrieval of plant biophysical and biochemical estimates. Previous studies have demonstrated that directional measurements contain added information that may increase the accuracy of estimated plant structural parameters. Because accurate biochemistry mapping is linked to vegetation structure, also models to estimate canopy nitrogen concentration (CN) may be improved indirectly from using multiangular data. Hyperspectral imagery with five different viewing zenith angles was acquired by the spaceborne CHRIS sensor over a forest study site in Switzerland. Fifteen canopy reflectance spectra corresponding to subplots of field-sampled trees were extracted from the preprocessed CHRIS images and subsequently two-term models were developed by regressing CN on four datasets comprising either original or continuum-removed reflectances. Consideration is given to the directional sensitivity of the CN estimation by generating regression models based on various combinations (n=15) of observation angles. The results of this study show that estimating canopy CN with only nadir data is not optimal irrespective of spectral data processing. Moreover adding multiangular information improves significantly the regression model fits and thus the retrieval of forest canopy biochemistry. These findings support the potential of multiangular Earth observations also for application-oriented ecological monitoring

A dynamic programming model for designing a quality control plan in a manufacturing process

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Process quality planning should establish the quality control plan to achieve the desired quality level with the minimum quality cost (appraisal and failure costs) for the final product. This plan sets out the critical quality variables, the control stations in the process, and the control method at each control station. The quality costs associated with quality control and defective products can be greater than or less than ideal regarding the required quality level. The purpose of this paper is to provide a stochastic dynamic programming model for designing the quality control plan in a manufacturing process, which allows obtaining the desired level of control with the lowest cost. Inputs to the model are, in particular, control stations in the process, levels of quality, control methodologies (no control, statistical process control, 100% inspection), probabilities of changing the quality level and quality costs. The output of this model is the quality control plan that satisfies the desired level of quality at the lowest cost. This plan establishes the control stations, the methodology used in each control station, the desired quality level for the final product, and the estimated quality costs. Finally, an illustrative example based on a manufacturing process demonstrates the applicability of this approach and several considerations are reported about future research directions.FCT - Fundação para a Ciência e a Tecnologia(UID/CEC/00319/2019

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies:a systematic review

Introduction: Understanding the clinical potency of latency-reversing agents (LRAs) on the HIV-1 reservoir is useful to deploy future strategies. This systematic review evaluated the effects of LRAs in human intervention studies. Methods: A literature search was performed using medical databases focusing on studies with adults living with HIV-1 receiving LRAs. Eligibility criteria required participants from prospective clinical studies, a studied compound hypothesised as LRA, and reactivation or tolerability assessments. Relevant demographical data, LRA reactivation capacity, reservoir size, and adverse events were extracted. A study quality assessment with analysis of bias was performed by RoB 2 and ROBINS-I tools. The primary endpoints were HIV-1 reservoir reactivation after LRA treatment quantified by cell-associated unspliced HIV-1 RNA, and LRA tolerability defined by adverse events. Secondary outcomes were reservoir size and the effect of LRAs on analytical treatment interruption (ATI) duration. Results: After excluding duplicates, 5182 publications were screened. In total 45 publications fulfilled eligibility criteria including 26 intervention studies and 16 randomised trials. The risk of bias was evaluated as high. Chromatin modulators were the main investigated LRA class in 24 studies. Participants were mostly males (90.1%). Where reported, HIV-1 subtype B was most frequently observed. Reactivation after LRA treatment occurred in 78% of studies and was observed with nearly all chromatin modulators. When measured, reactivation mostly occurred within 24 h after treatment initiation. Combination LRA strategies have been infrequently studied and were without synergistic reactivation. Adverse events, where reported, were mostly low grade, yet occurred frequently. Seven studies had individuals who discontinued LRAs for related adverse events. The reservoir size was assessed by HIV-1 DNA in 80% of studies. A small decrease in reservoir was observed in three studies on immune checkpoint inhibitors and the histone deacetylase inhibitors romidepsin and chidamide. No clear effect of LRAs on ATI duration was observed. Conclusion: This systematic review provides a summary of the reactivation of LRAs used in current clinical trials whilst highlighting the importance of pharmacovigilance. Highly heterogeneous study designs and underrepresentation of relevant patient groups are to be considered when interpreting these results. The observed reactivation did not lead to cure or a significant reduction in the size of the reservoir. Finding more effective LRAs by including well-designed studies are needed to define the required reactivation level to reduce the HIV-1 reservoir.</p

Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health.

The 20th International Symposium on HIV and Emerging Infectious Diseases took place in Marseille, France. It had a refreshing European look with reinforced partnerships with the European AIDS Clinical Society and the British HIV Association and with international speakers and participants. Topics included HIV and global health, HIV and hepatitis cure, the microbiome and immunotherapies, clinical research and methodology, as well as chemsex, pre-exposure prophylaxis, sexually transmitted infections and emerging infectious diseases. Novel areas of research were also described, such as electronic technology in order to improve HIV management, and the expert patient

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review

Introduction: Understanding the clinical potency of latency-reversing agents (LRAs) on the HIV-1 reservoir is useful to deploy future strategies. This systematic review evaluated the effects of LRAs in human intervention studies. Methods: A literature search was performed using medical databases focusing on studies with adults living with HIV-1 receiving LRAs. Eligibility criteria required participants from prospective clinical studies, a studied compound hypothesised as LRA, and reactivation or tolerability assessments. Relevant demographical data, LRA reactivation capacity, reservoir size, and adverse events were extracted. A study quality assessment with analysis of bias was performed by RoB 2 and ROBINS-I tools. The primary endpoints were HIV-1 reservoir reactivation after LRA treatment quantified by cell-associated unspliced HIV-1 RNA, and LRA tolerability defined by adverse events. Secondary outcomes were reservoir size and the effect of LRAs on analytical treatment interruption (ATI) duration. Results: After excluding duplicates, 5182 publications were screened. In total 45 publications fulfilled eligibility criteria including 26 intervention studies and 16 randomised trials. The risk of bias was evaluated as high. Chromatin modulators were the main investigated LRA class in 24 studies. Participants were mostly males (90.1%). Where reported, HIV-1 subtype B was most frequently observed. Reactivation after LRA treatment occurred in 78% of studies and was observed with nearly all chromatin modulators. When measured, reactivation mostly occurred within 24 h after treatment initiation. Combination LRA strategies have been infrequently studied and were without synergistic reactivation. Adverse events, where reported, were mostly low grade, yet occurred frequently. Seven studies had individuals who discontinued LRAs for related adverse events. The reservoir size was assessed by HIV-1 DNA in 80% of studies. A small decrease in reservoir was observed in three studies on immune checkpoint inhibitors and the histone deacetylase inhibitors romidepsin and chidamide. No clear effect of LRAs on ATI duration was observed. Conclusion: This systematic review provides a summary of the reactivation of LRAs used in current clinical trials whilst highlighting the importance of pharmacovigilance. Highly heterogeneous study designs and underrepresentation of relevant patient groups are to be considered when interpreting these results. The observed reactivation did not lead to cure or a significant reduction in the size of the reservoir. Finding more effective LRAs by including well-designed studies are needed to define the required reactivation level to reduce the HIV-1 reservoir